User login
Highlights in Ovarian Cancer From ASCO 2020
The DESKTOP III trial, whose results were eagerly awaited, compared surgery followed by chemotherapy versus chemotherapy only in recurrent platinum-sensitive ovarian cancer. Dr. Maurie Markman, from Cancer Treatment Centers of America in Philadelphia, reports that the DESKTOP results, initially announced in 2017, continue to show an improvement in progression-free survival in favor of surgery plus chemotherapy.
Dr. Markman next comments on the SOLO-2 study assessing maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation, which showed significantly improved overall survival for patients receiving olaparib.
Among other olaparib trials, the phase 3 PAOLA-1 study looked at olaparib plus bevacizumab in platinum-sensitive recurrent ovarian cancer. The study explored the efficacy of this combination in treating tumors with BRCA1/BRCA2 mutations and found that all patients benefited.
Finally, Dr. Markman reports on noteworthy abstracts, including studies examining the adequacy of genetic testing and real-world data in management of patients with ovarian cancer.
Maurie Markman, MD
Maurie Markman, MD, Clinical Professor of Medicine, Drexel University College of Medicine; President, Medicine & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania. Maurie Markman, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck, Inc. Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP
The DESKTOP III trial, whose results were eagerly awaited, compared surgery followed by chemotherapy versus chemotherapy only in recurrent platinum-sensitive ovarian cancer. Dr. Maurie Markman, from Cancer Treatment Centers of America in Philadelphia, reports that the DESKTOP results, initially announced in 2017, continue to show an improvement in progression-free survival in favor of surgery plus chemotherapy.
Dr. Markman next comments on the SOLO-2 study assessing maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation, which showed significantly improved overall survival for patients receiving olaparib.
Among other olaparib trials, the phase 3 PAOLA-1 study looked at olaparib plus bevacizumab in platinum-sensitive recurrent ovarian cancer. The study explored the efficacy of this combination in treating tumors with BRCA1/BRCA2 mutations and found that all patients benefited.
Finally, Dr. Markman reports on noteworthy abstracts, including studies examining the adequacy of genetic testing and real-world data in management of patients with ovarian cancer.
Maurie Markman, MD
Maurie Markman, MD, Clinical Professor of Medicine, Drexel University College of Medicine; President, Medicine & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania. Maurie Markman, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck, Inc. Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP
The DESKTOP III trial, whose results were eagerly awaited, compared surgery followed by chemotherapy versus chemotherapy only in recurrent platinum-sensitive ovarian cancer. Dr. Maurie Markman, from Cancer Treatment Centers of America in Philadelphia, reports that the DESKTOP results, initially announced in 2017, continue to show an improvement in progression-free survival in favor of surgery plus chemotherapy.
Dr. Markman next comments on the SOLO-2 study assessing maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation, which showed significantly improved overall survival for patients receiving olaparib.
Among other olaparib trials, the phase 3 PAOLA-1 study looked at olaparib plus bevacizumab in platinum-sensitive recurrent ovarian cancer. The study explored the efficacy of this combination in treating tumors with BRCA1/BRCA2 mutations and found that all patients benefited.
Finally, Dr. Markman reports on noteworthy abstracts, including studies examining the adequacy of genetic testing and real-world data in management of patients with ovarian cancer.
Maurie Markman, MD
Maurie Markman, MD, Clinical Professor of Medicine, Drexel University College of Medicine; President, Medicine & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania. Maurie Markman, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck, Inc. Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; Clovis; Tesaro; AstraZeneca Pharmaceuticals, LP
